Key Highlights

• Donald Trump has proposed a 100 percent tariff on imported generic medicines from 2028.

• The tariff will increase to 200 percent a year later under the current proposal.

• No tariff will be imposed during the two-year transition period beginning August 1.

• The proposal aims to boost domestic pharmaceutical manufacturing in the United States.

• Indian pharmaceutical companies could reassess manufacturing and investment plans.

• Larger companies may adapt more easily than smaller exporters due to stronger financial resources.

• The proposal creates long-term uncertainty but is unlikely to have an immediate impact on earnings.

Trump Proposes Major Shift in US Pharmaceutical Policy

US President Donald Trump has announced a major policy proposal aimed at reducing the United States' dependence on imported medicines by encouraging pharmaceutical companies to manufacture more drugs within the country. The proposal includes steep tariffs on imported generic medicines but also provides companies with a two-year transition period to shift production before the new duties take effect.

The announcement represents one of the strongest trade measures ever proposed for the pharmaceutical industry. The policy is designed to strengthen domestic manufacturing, improve supply-chain security, and reduce reliance on overseas suppliers following the supply disruptions experienced during the COVID-19 pandemic.

Tariff Timeline Gives Companies Time to Prepare

According to the proposal, no tariff will be imposed on imported generic medicines during the two-year transition period beginning on August 1. This window is intended to give pharmaceutical companies sufficient time to plan investments and relocate manufacturing operations if required.

From 2028, imported generic medicines would face a 100 percent tariff. A year later, the tariff would increase further to 200 percent if the proposal is implemented in its current form.

The phased approach is expected to encourage companies to begin expanding manufacturing capacity in the United States before the tariffs become effective.

Why the United States Is Introducing the Policy

The proposed policy is part of a broader strategy to strengthen America's pharmaceutical supply chain and improve national healthcare security.

During the pandemic, disruptions in global manufacturing highlighted the risks of relying heavily on imported medicines and pharmaceutical ingredients. By promoting domestic production, the US government aims to improve the availability of essential medicines during emergencies while creating new manufacturing jobs and attracting fresh investment.

The proposal also aligns with broader efforts to increase domestic manufacturing across several strategic industries.

What It Means for Indian Pharmaceutical Companies

India is the world's largest supplier of generic medicines by volume and exports a significant share of its pharmaceutical products to the United States. Many leading Indian drug manufacturers generate an important portion of their revenue from the US generics market.

If tariffs of this scale are introduced, exporting medicines from India to the US would become significantly more expensive. Companies may have to absorb part of the higher costs, increase product prices, or shift manufacturing closer to the American market to remain competitive.

The two-year transition period provides valuable time for companies to review their business strategies before any tariffs are imposed.

Companies Likely to Review Their US Manufacturing Strategy

Several leading Indian pharmaceutical companies are expected to closely examine their long-term manufacturing plans if the proposal progresses toward implementation.

These companies may consider :

• Expanding existing manufacturing facilities in the United States.

• Building new production plants.

• Acquiring US-based manufacturing businesses.

• Partnering with American contract manufacturing companies.

• Diversifying production across multiple countries to reduce future trade risks.

Companies including Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Cipla, Lupin, Aurobindo Pharma, Zydus Lifesciences, and Torrent Pharmaceuticals are among those likely to evaluate their exposure to the US market and future investment requirements.

Larger pharmaceutical companies with stronger financial resources and existing international manufacturing networks may find it easier to adapt. Smaller exporters that rely mainly on production in India could face greater competitive challenges if the tariffs are eventually introduced.

Impact on the Global Pharmaceutical Industry

The proposal has implications that extend beyond India and the United States.

Global pharmaceutical companies may increasingly move manufacturing closer to major markets to reduce trade risks and improve supply-chain resilience. This could lead to fresh investments in North America while encouraging companies to diversify manufacturing locations rather than depending heavily on a single country.

If implemented, the policy could reshape global supply chains over the coming years as companies adjust production strategies to maintain access to the US market.

Potential Benefits and Challenges for the United States

The proposed tariffs could support domestic pharmaceutical manufacturing by encouraging companies to establish production facilities within the United States. This may generate new employment opportunities, strengthen industrial capacity, and improve long-term supply security.

However, domestic manufacturing generally involves higher production costs than importing generic medicines from countries such as India. If these higher costs are passed on to consumers, healthcare expenses in the United States could increase, particularly for affordable generic medicines that are widely used.

The final economic impact will depend on how quickly companies establish manufacturing facilities and whether domestic production can meet market demand at competitive prices.

What Investors Should Watch

For investors, the proposal introduces long-term policy uncertainty rather than an immediate financial impact. Since no tariffs will apply during the next two years, pharmaceutical companies have time to adjust their manufacturing and investment strategies.

Investors should closely monitor several developments over the coming months, including :

• The final structure of the proposed tariff policy.

• Possible exemptions for specific medicines or manufacturers.

• Industry lobbying and feedback from pharmaceutical companies.

• Trade negotiations between the United States and its trading partners.

• Announcements of new manufacturing investments and acquisitions.

These factors will determine whether the proposal becomes a major structural change for the global generic drug industry or evolves into a more targeted trade measure.

Conclusion

Donald Trump's proposal marks a significant shift in US pharmaceutical trade policy and has the potential to reshape the global generic medicines industry. While the proposed tariffs are among the highest ever announced for pharmaceutical imports, the two-year transition period gives companies time to adapt before any duties are imposed.

For Indian pharmaceutical companies, the coming years will be crucial for evaluating manufacturing strategies, investment plans, and supply-chain diversification. At the same time, investors and industry participants will closely watch policy developments to understand whether the proposal is implemented in its current form or modified through negotiations before taking effect.